This suggests that nultin-3a has a significant potential for treating KRAS MT/p53 WT NSCLC cells and overcoming the resistance developed by cancer cells, which currently has limited treatment options, even though the underlying mechanism needs to be further investigated. This evidence concerns the gene TP53 and cancer.